title: Effect of CXCL10 receptor antagonist on islet cell apoptosis in a type I diabetes rat model.
abstract: In recent years, the incidence of type 1 diabetes mellitus (T1DM) has been increasing. The role of CXCL10 and its receptor, CXCR3, in the occurrence of T1DM has drawn lots of research interests, as the disease incidence was correlated with their expression levels. We thus used an antagonist of CXCR3, NBI-74330, to block the specific binding, for further observation of islet cell apoptosis in a T1MD rat model. A total of 80 SD rats were given STZ intraperitoneally for generating T1DM model. Different concentrations of NBI-74330 were then applied, followed by the collection of blood and pancreatic tissue samples. CXCL10 and CXCR3 levels were detected by enzyme linked immunosorbent assay (ELISA), followed by expressional assays in pancreatic tissues by real-time PCR, Western blotting and flow cytometry. Compared to control group, model rats had significantly elevated blood glucose level (>16.7 mmol/L), with depressed CXCL10 and CXCR3 levels compared to model group (P<0.05). After NBI-74330 treatment, mRNA and protein levels of CXCL10 and CXCR3 were significantly lowered, with significantly decreased apoptotic cell ratios compared to model group (P<0.05). CXCL10 receptor antagonist NBI-74330 can inhibit the apoptosis of pancreatic islet cells in T1DM rats.
authors.affiliation: Department of Pediatrics, Zhangzhou Hospital Affiliated to Fujian Medical University Zhangzhou 363000, Fujian, P. R. China.
authors.forename: Jinshui
authors.initials: J
authors.lastname: He
authors.affiliation: Department of Pediatrics, Zhangzhou Hospital Affiliated to Fujian Medical University Zhangzhou 363000, Fujian, P. R. China.
authors.forename: Chaowei
authors.initials: C
authors.lastname: Lian
authors.affiliation: Department of Pediatrics, Zhangzhou Hospital Affiliated to Fujian Medical University Zhangzhou 363000, Fujian, P. R. China.
authors.forename: Yanling
authors.initials: Y
authors.lastname: Fang
authors.affiliation: Department of Endocrine, Zhangzhou Hospital Affiliated to Fujian Medical University Zhangzhou 363000, Fujian, P. R. China.
authors.forename: Jinzhi
authors.initials: J
authors.lastname: Wu
authors.affiliation: Department of Pathology, Zhangzhou Hospital Affiliated to Fujian Medical University Zhangzhou 363000, Fujian, P. R. China.
authors.forename: Jianning
authors.initials: J
authors.lastname: Weng
authors.affiliation: Department of Pediatrics, Zhangzhou Hospital Affiliated to Fujian Medical University Zhangzhou 363000, Fujian, P. R. China.
authors.forename: Xiaoling
authors.initials: X
authors.lastname: Ye
authors.affiliation: Department of Pediatrics, Zhangzhou Hospital Affiliated to Fujian Medical University Zhangzhou 363000, Fujian, P. R. China.
authors.forename: Huowang
authors.initials: H
authors.lastname: Zhou
mesh_terms: D000081:Acetamides / Q000494:pharmacology*; D000818:Animals; D017209:Apoptosis / Q000187:drug effects* / Q000502:physiology; D015153:Blotting, Western; D054357:Chemokine CXCL10 / Q000378:metabolism; D003921:Diabetes Mellitus, Experimental / Q000378:metabolism / Q000473:pathology*; D003922:Diabetes Mellitus, Type 1 / Q000378:metabolism / Q000473:pathology*; D004797:Enzyme-Linked Immunosorbent Assay; D005434:Flow Cytometry; D007515:Islets of Langerhans / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D008297:Male; D011743:Pyrimidines / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D060888:Real-Time Polymerase Chain Reaction; D054367:Receptors, CXCR3 / Q000037:antagonists & inhibitors*
chemical_list: D000081:Acetamides; D054357:Chemokine CXCL10; C091326:Cxcl10 protein, rat; C515189:Cxcr3 protein, rat; C501976:NBI-74330; D011743:Pyrimidines; D054367:Receptors, CXCR3
keywords: CXCL10; CXCR3; NBI-74330; Type 1 diabetes mellitus
references.citation: Diabetes Metab Res Rev. 2010 Jan;26(1):33-9
references.pmid: 19943328
references.citation: Ther Adv Endocrinol Metab. 2015 Jun;6(3):87-91
references.pmid: 26137212
references.citation: Cytokine Growth Factor Rev. 2014 Feb;25(1):57-65
references.pmid: 24529741
references.citation: Carcinogenesis. 2011 Feb;32(2):129-37
references.pmid: 21051441
references.citation: Arterioscler Thromb Vasc Biol. 2008 Feb;28(2):251-7
references.pmid: 18048768
references.citation: PLoS One. 2015;10(7):e0132716
references.pmid: 26181330
references.citation: Immunology. 2011 Apr;132(4):503-15
references.pmid: 21255008
references.citation: Cytokine. 2013 Feb;61(2):337-9
references.pmid: 23265968
references.citation: Br J Cancer. 2015 Jul 14;113(2):327-35
references.pmid: 26042934
references.citation: Clin Exp Immunol. 2010 Mar;159(3):338-43
references.pmid: 20059481
references.citation: PLoS One. 2015;10(5):e0125349
references.pmid: 25933189
references.citation: Cardiovasc Res. 2014 Jul 15;103(2):217-27
references.pmid: 24891401
references.citation: Clin Ter. 2014;165(3):e237-42
references.pmid: 24999582
references.citation: J Nutr Educ Behav. 2015 Jul-Aug;47(4):361-6.e1
references.pmid: 26164132
references.citation: Lancet. 2009 Jun 13;373(9680):1999-2000
references.pmid: 19481250
references.citation: Autoimmun Rev. 2015 Sep;14(9):781-97
references.pmid: 26001590
references.citation: Cancer Immunol Res. 2015 Aug;3(8):864-70
references.pmid: 26025380
references.citation: Mol Pharmacol. 2014 Jan;85(1):116-26
references.pmid: 24174496
references.citation: Inflammation. 2013 Apr;36(2):364-71
references.pmid: 23065240
references.citation: Cell Metab. 2009 Feb;9(2):125-39
references.pmid: 19187771